Today Stories

Heidelberg Pharma Announces First Patient Dosed with Antibody Targeted Amanitin Conjugate HDP-101 in Multiple Myeloma Ladenburg, Germany, 15 February 2022 - Heidelberg Pharma AG (FSE: HPHA) today announced that the first patient has been dosed with HDP-101 in a Phase I/IIa study at the Winship Cancer Institute of Emory University, Atlanta, GA, USA. The open-label, multi-center Phase I/IIa study will evaluate HDP-101, a BCMA antibody-Amanitin conjugate, for the treatment of relapsed or refractory multiple myeloma, a bone marrow cancer with high unmet medical need. Dr. András Strassz, Chief Medical Officer of Heidelberg Pharma, commented: "It is an important step for Heidelberg Pharma to have the first patient dosed in our study. This Phase I/IIa study will test a new mode of action in oncol…

PARIS--(BUSINESS WIRE)--On the occasion of World Epilepsy Day (14th of February 2022), Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy. Epilepsy is a common neurological disorder that typically results in seizures of various types, with focal seizures being the most common.1 The essential treatment goal of epilepsy therapy is freedom from seizures.2 The global disease burden of epilepsy is high.3,4 A diagnosis of epilepsy confers significant disability on the individual, including physical, psychological, and social issues that negatively impact self-esteem, family environment, relationships, leisure and working life.3,5 Long-term outcomes for…

The Cell and Gene Therapy Catapult has partnered with MICA Biosystems to begin the journey of bringing their revolutionary regenerative medicine technology to the MHRA. London 10th February 2022: The Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specialising in the advancement of cell and gene therapies, announces a collaboration with MICA Biosystems (MICA), a Birmingham based medical technology company, to leverage the expertise of the CGT Catapult in taking novel technologies and concepts through to clinical trials. MICA have developed a ground-breaking platform that uses patented nanotechnology to control a patient’s stem cells, in situ, to repair or replace damaged or diseased tissue. The first application of MICA’s technology is i…

Arrangement Includes Labcorp’s Acquisition of Certain Outreach Laboratory Assets Strategic Collaboration Expands Patient Access to Labcorp’s Services, Drives Efficiencies and Advances Clinical Innovation BURLINGTON, N.C.--(BUSINESS WIRE)--Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has entered into agreements to create a comprehensive strategic relationship with Ascension, one of the nation’s leading Catholic and non-profit health systems. Through the expansive strategic collaboration, Labcorp will manage Ascension’s hospital-based laboratories in 10 states and purchase select assets of the health system’s outreach laboratory business. This long-term relationship will expand Labcorp’s clinical laboratory services in several states across the countr…

Paris, February 8, 2022. Sanofi announced today the completion of its acquisition of Amunix Pharmaceuticals, Inc, adding a promising pipeline of T-cell engagers and cytokine therapies. The acquisition also provides access to Amunix Pro-XTEN, XPAT, and XPAC technology to deliver next generation Conditionally Activated Biologics. The technology platform is highly complementary to Sanofi’s existing R&D platforms and supports Sanofi’s efforts to accelerate and expand its contributions to innovative medicines for oncology patients, with approximately 20 molecules currently in development. Weil, Gotshal & Manges LLP is acting as Sanofi’s legal counsel. Centerview Partners LLC is acting as financial advisor to Amunix and Fenwick & West LLP is acting as its legal counsel. About SanofiW…

Agreement brings complementary capabilities in clinical, regulatory and scientific affairs for clients in key markets Frankfurt, Germany – 8 January 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced a merger agreement with Ascent Development Services, a Japan-based leader in enabling the integration of  Asia into global pharmaceutical product development. Founded in 2017, Ascent’s team of experts work with emerging biopharma companies to understand and overcome differences in medical practice, culture and language in order to achieve the optimal strategic and operational integration of Asia into global drug development.  Headquartered in Tokyo, Ascent employs staff across Asia, including China, Korea, M…

Ortenberg, 7th February 2022. BMG LABTECH introduced the new VANTAstarTM microplate reader, further expanding its range of high-quality, made-in-Germany instruments. The latest addition to the BMG LABTECH portfolio, the VANTAstar was conceived for ease-of-use and flexibility for a wide range of applications in basic research and life sciences. The VANTAstar was officially introduced to public at the SLAS 2022 conference and exhibition in Boston, USA. Flexible microplate reader with simplified workflows The VANTAstar is a compact multi-mode microplate reader and is equipped with three features that enable an effortless detection setup and improve data quality: Enhanced Dynamic Range (EDR) technology, a rapid full-plate auto-focus and automatic luminescence cross-talk reduction. The EDR tech…

To mark World Cancer Day on 4th February, EIT Health vows to back innovative technologies to support early screening and cancer diagnosis EIT Health says that earlier diagnosis will save money on treatment – allowing for savings that can be reinvested into better services Without concerted action, cancer cases are expected to increase by 25 per cent by 2035 making it the leading cause of death in the EU[1] EIT Health, part of the European Institute of Innovation and Technology, today marks World Cancer Day by vowing to back more innovative technologies that can help to support early screening and diagnosis of cancer in a bid to ‘Close the Care Gap’ and help provide equitable care for all. This year’s World Cancer Day’s theme is all about raising awareness of the equity gap that affects…

As the COVID-19 pandemic continues to have a disproportionate impact on women, Organon issues a call to action for other leaders to create opportunities to focus on women’s health in the UK LONDON, UK — Organon (NYSE: OGN), a global women’s health company, is designating International Women’s Day (IWD) on 8th March as a day to recognise the growing health disparities that women face that have been exacerbated by the COVID-19 pandemic. Since its inception, IWD has focused on accelerating gender parity. Organon recognises the need for a global effort to address her health and understands that it needs to start with its own employees by giving them paid time off to attend to their own health needs. The company is also inviting organisations in the UK and across the globe to join in raising aw…

Nina Capital, APEX Medical and Cambridge Enterprise invest in transformational open-source data technology – to deliver precision medicine at scale   LONDON, UK. February 1, 2022:  University of Cambridge technology spin-out Zetta Genomics announces that is has raised £2.5 million in new seed funding. The successful round secures leading global Venture Capital (VC) investment in the company’s XetaBase platform – a transformational genomic data management technology that powers the discovery and delivery of precision medicine at scale.   Data for the precision medicine era  Built on the open-source OpenCB platform, co-developed by Zetta Genomics founder, Ignacio Medina, XetaBase allows researchers and clinicians to securely store, easily access and dynamically interrogate vast and increasin…

Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient need Basel, 31 January 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo™ (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). Neovascular AMD and DME are two leading causes of vision loss worldwide.1 Vabysmo targets and inhibits two disease pathways linked to a number of vision-threatening retinal conditions by neutralisin…

Parenteral and device manufacturing site will increase the number of people around the world who may benefit from Lilly's medicines INDIANAPOLIS, Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) plans to invest over $1 billion to create a new manufacturing site, along with nearly 600 new jobs in Concord, North Carolina. The brand-new facility will utilize the latest technology to manufacture parenteral (injectable) products and devices and increase the company's manufacturing capacity. "Lilly is entering an exciting period of growth and we are committed to delivering innovative medicines to patients around the world," said Edgardo Hernandez, senior vice president and president, Lilly Manufacturing Operations. "Expanding our manufacturing footprint in North Carolina enables…

Phase 1 trial aims to build on response seen in proof-of-concept trial CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses have been administered in a clinical trial of experimental HIV vaccine antigens at George Washington University (GWU) School of Medicine and Health Sciences in Washington, D.C. The Phase 1 trial, IAVI G002, is designed to test the hypothesis that sequential administration of priming and boosting HIV immunogens delivered by messenger RNA (mRNA) can induce specific classes of B-cell responses and guide their early maturation toward broadly neutralizing antibody (bnAb) development. The induction of bnAbs is widely considered to be a goal of…

Cardiff, UK, January 24, 2022 - TrakCel, a leading supplier of cellular orchestration solutions for the cell and gene therapy industry, today announces it is launching a software integration resulting from a collaborative, non-exclusive partnership with Körber, the specialists for complete handling systems for pharmaceutical and medical products. The collaboration results in a working integration between OCELLOS by TrakCel and PAS-X from Körber. This will allow cell and gene therapy customers of both companies to effectively share data detailing manufacturing events, and milestones between the two systems such as starting checks, fill and finish and product release, whilst also providing full traceability and audit logs. TrakCel’s OCELLOS has ensured that developers and other cell and gene…

Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomnia Collaboration with Syneos Health to effectively reach the primary care market in Europe and Canada Allschwil, Switzerland & Morrisville, N.C. – January 26, 2022Idorsia Ltd (SIX: IDIA), a leading Swiss biopharmaceutical company, and Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada. Simon Jose, Chief Commercial Officer of Idorsia, comm…

Merger continues commitment to innovation and strengthens tech-enablement and automation Frankfurt, Germany – 25 January 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medtech industries worldwide, has announced a merger with leading technology and services organization for clinical and regulatory solutions, Phlexglobal. Founded in 1997, Phlexglobal provides its industry-leading and innovative electronic Trial Master File platform (PhlexTMF) and services to hundreds of global life sciences companies and AI-enabled automation solutions that allow customers to benefit from existing clinical and regulatory training models.   Phlexglobal’s staff of more than 400 people – based in the United Kingdom, the United States, India, Poland and Germany – b…

DUBAI, Arab Emirates, January 21, 2022 (Newswire.com) - AiPharma, a global biopharmaceutical company developing and commercializing innovative antiviral therapies, has completed an extensive rebranding effort in response to accelerated company growth and to reflect the business's expanded strategy. The company has undergone a significant transformation at the beginning of 2022 and has decided to relaunch its business under the new brand name Cellvera. The name Cellvera, originated from Latin, breaks down to 'cell' - which is referred to as the smallest yet fundamental unit of life in which the DNA code is being stored, and 'vera' which means true. This name represents the company and aligns with its beliefs and approach towards the science in which lies the truth of life and health encoded…

Achieved Global Recognition And Top Employer Certification In 39 Countries From Top Employers Institute® Recognition Highlights Takeda’s Unwavering Commitment To Its People OSAKA, Japan and CAMBRIDGE, Massachusetts, January 19, 2022 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was one of only 11 companies to achieve global Top Employer® certification for 2022, marking the fifth consecutive year that it has been recognized for outstanding people policies and practices worldwide. In addition to the global certification, Takeda is also recognized as a Top Employer across four regions and 39 countries, reinforcing its steadfast commitment to create a diverse and inclusive organization that enables its people to thrive.    Established more…

Boehringer Ingelheim advances to one of eleven global top employers worldwide  Awards in 29 countries and in Europe, the Latin America, and Asia-Pacific regions  High scores in values, ethics and integrity serve as a driver for a strong corporate innovation culture  Ingelheim, Germany, January 20, 2022 – The Top Employers Institute awarded Boehringer Ingelheim for the second year in succession a “Global Top Employer”, one of the world’s eleven best employers. The award shows that the research-driven pharmaceutical company is strongly oriented to the needs and well-being of its employees. Boehringer Ingelheim has been listed among the top employers in many countries and regions for the past eight years. This year, Boehringer Ingelheim will receive the award in 29 countries, as well as…

Merger extends reach in key Italian marketplace and broadens market access expertise  Frankfurt, Germany – January 18th 2022: PharmaLex Group, a leading provider of specialized services for the pharma, biotech and medical device industries worldwide, has announced a merger with MAP Group, Italy’s leading provider of market access services.  Founded in 2010 by Elena Paola Lanati, MAP Group comprises three companies: MA Provider, MAPCOM Consulting and 3P Solution, which together deliver high-quality expertise across the product life cycle -- from negotiation strategy, to local market access, to market launch.  MAP Group’s staff of more than 70 experts support a large number of new drugs for market entry in Italy, providing integrated market access, communication and educational services. The…